Chemotherapy-induced peripheral neuropathy (CIPN) is one of the serious side effects of cancer chemotherapy and significantly reduces the quality of life of patients. However, there are no effective treatments or therapeutic agents for CIPN. Therefore, it is a serious problem in the continuation of anticancer drug therapy. A novel gabapentinoid, mirogabalin (MGB), is used as a treatment for neuropathic pain. In this study, in order to develop a new treatment, we investigated the preventive effects of MGB on mechanical allodynia in a mouse model of vincristine (VCT) -induced peripheral neuropathic pain (VIPN). A single oral administration of MGB dose-dependently inhibited VCT-induced mechanical allodynia. Next, to investigate the action sites of MGB, we evaluated the topical analgesic effects on VIPN model mice.  We found that intrathecal injection suppressed VCT-induced mechanical allodynia but intradermal injection into the footpad did not. Furthermore, intrathecal injection of MGB in healthy mice did not affect locomotor activity. In addition, prophylactic repeated administration of MGB suppressed VCT-induced mechanical allodynia. These results indicate that MGB prophylactically suppresses VIPN by acting on the spinal dorsal horn. MGB may be an effective therapeutic agent for VIPN.